Compare · JNJ vs THAR
JNJ vs THAR
Side-by-side comparison of Johnson & Johnson (JNJ) and Tharimmune Inc. (THAR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and THAR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $613.10B.
- JNJ has hit the wire 18 times in the past 4 weeks while THAR has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for THAR).
- Company
- Johnson & Johnson
- Tharimmune Inc.
- Price
- -
- -
- Market cap
- $613.10B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 18
- 0
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
- Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
- Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
- Johnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
Latest THAR
- Tharimmune Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy
- SEC Form 3 filed by new insider Radkowski Angela Dominy
- SEC Form 3 filed by new insider Sommers Jill E.
- SEC Form 3 filed by new insider Wiley William Thomas Jr.
- SEC Form 3 filed by new insider Asbury Jacob
- SEC Form SCHEDULE 13G filed by Tharimmune Inc.
- Tharimmune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer
- SEC Form SCHEDULE 13G filed by Tharimmune Inc.